David R. Bauer

Davis Polk advised Centogene N.V. on its $49 million follow-on public offering of 3,500,000 of its common shares, consisting of 2,000,000 common shares offered by Centogene and 1,500,000…

Davis Polk advised the underwriters in connection with a public offering of 6,900,000 shares of common stock of Revolution Medicines, Inc. at $26.00 per share (which includes the…

Davis Polk advised the joint book-running managers and representatives of the underwriters in connection with the $69 million follow-on offering of common stock of Magenta Therapeutics…

Davis Polk advised the sole book-running manager in connection with the $215.6 million common stock offering of 6,900,000 shares of common stock of Editas Medicine, Inc. The common…

Davis Polk advised the joint book-running managers and representatives of the several underwriters in connection with the $192.5 million offering of common stock of Constellation…

Davis Polk advised Shockwave Medical, Inc. on its SEC-registered public offering of 1,955,000 shares of common stock for an aggregate price to the public of approximately $89.4 million,…

Davis Polk advised Royalty Pharma plc and the selling shareholders on Royalty Pharma’s $2.5 billion initial public offering of 89,333,920 of its Class A ordinary shares, which included an…

Davis Polk advised the representatives of the underwriters in connection with the $230 million initial public offering of 12,105,263 shares of common stock of Generation Bio Co., which…

Davis Polk advised the sales agent in connection with an SEC-registered at-the-market offering by Applied Therapeutics, Inc. of shares of its common stock for up to a maximum offering…

Davis Polk is advising Novo Nordisk A/S on its acquisition of Corvidia Therapeutics Inc. for an upfront payment of $725 million in cash. Total payments to Corvidia Therapeutics shareholders…